az-9773
Trade name: CytoFab
Animal productexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00615017)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109587 ↗
Also known as
- az9773
- az-9773
- azd9773
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01145560 | Phase 2 | Oct 1, 2010 | AstraZeneca, Parexel, Vanderbilt University |
| NCT01144624 | Phase 2 | Jul 1, 2010 | AstraZeneca, Parexel |
| NCT00615017 | Phase 2 | Jan 1, 2008 | AstraZeneca, Parexel |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 1 | 2008 |
| Parexel | For profit | 3 | 0 | 1 | 2008 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1